Peter Altman - BioCardia President CEO
CEO
Peter Altman is President CEO of BioCardia
| Age | 57 |
| Phone | 650 226 0120 |
| Web | https://www.biocardia.com |
Peter Altman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Altman against BioCardia stock is an integral part of due diligence when investing in BioCardia. Peter Altman insider activity provides valuable insight into whether BioCardia is net buyers or sellers over its current business cycle. Note, BioCardia insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioCardia'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Altman over two months ago Acquisition by Peter Altman of 1000 shares of Biocardia at 2.4877 subject to Rule 16b-3 | ||
Peter Altman over three months ago Acquisition by Peter Altman of 3100 shares of Biocardia at 1.87 subject to Rule 16b-3 |
BioCardia Management Efficiency
The company has return on total asset (ROA) of (1.3267) % which means that it has lost $1.3267 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.0362) %, meaning that it generated substantial loss on money invested by shareholders. BioCardia's management efficiency ratios could be used to measure how well BioCardia manages its routine affairs as well as how well it operates its assets and liabilities. BioCardia (BCDAW) is traded on NASDAQ Exchange in USA and employs 16 people.Management Performance
| Return On Equity | -7.04 | |||
| Return On Asset | -1.33 |
BioCardia Leadership Team
Elected by the shareholders, the BioCardia's board of directors comprises two types of representatives: BioCardia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioCardia. The board's role is to monitor BioCardia's management team and ensure that shareholders' interests are well served. BioCardia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioCardia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Altman, President CEO | ||
| Edward Gillis, Senior Devices | ||
| Sujith Shetty, Chief Regulatory | ||
| Sujith MBBS, Chief Regulatory | ||
| David McClung, Chief Officer |
BioCardia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioCardia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.04 | |||
| Return On Asset | -1.33 | |||
| Operating Margin | (41.36) % | |||
| Number Of Shares Shorted | 4.26 K | |||
| Revenue | 477 K | |||
| EBITDA | (11.23 M) | |||
| Net Income | (11.57 M) | |||
| Total Debt | 1.31 M | |||
| Book Value Per Share | (1.27) X | |||
| Cash Flow From Operations | (9.97 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in BioCardia Stock
If you are still planning to invest in BioCardia check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioCardia's history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |